Inhibition of the sodium glucose co-transporter-2: Its beneficial action and potential combination therapy for type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 15, Issue 5, 2013, Pages 392-402

  Chen, L H ^a   Leung, P S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Blood pressure; Body weight; Inflammation; Insulin sensitivity; Islet morphology; Preclinical clinical studies; Sodium glucose co transporter 2 inhibitors; Structural differences; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BI 38335; CANAGLIFLOZIN; DAPAGLIFLOZIN; EGT 1442; EMPAGLIFLOZIN; HEMOGLOBIN A1C; IPRAGLIFLOZIN; LINAGLIPTIN; METFORMIN; PHLORIZIN; PIOGLITAZONE; SAXAGLIPTIN; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 3; SODIUM GLUCOSE COTRANSPORTER 4; SODIUM GLUCOSE COTRANSPORTER 5; SODIUM GLUCOSE COTRANSPORTER 6; TS 071; UNCLASSIFIED DRUG;

BODY WEIGHT; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSURIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZHYDRYL COMPOUNDS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84876322415     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12064     Document Type: Review

References (82)

1. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-333.
2. Aschner P, Katzeff HL, Guo H et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-261.
3. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22: 1151-1168.
4. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-269.
5. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515.
6. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404.
7. Wright E. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10-F18.
8. Kothinti RK, Blodgett AB, North PE, Roman RJ, Tabatabai NM. A novel SGLT is expressed in the human kidney. Eur J Pharmacol 2012; 690: 77-83.
9. +-dependent glucose transporter, is an essential transporter for mannose, 1, 5-anhydro-D-glucitol, and fructose. Life Sci 2005; 76: 1039-1050.
10. Grempler R, Augustin R, Froehner S et al. Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett 2011; 586: 248-253.
11. 3H] inositol. J Biol Chem 1996; 271: 10073-10078.
12. Roll P, Massacrier A, Pereira S, Robaglia-Schlupp A, Cau P, Szepetowski P. New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families. Gene 2002; 285: 141-148.
13. Aouameur R, Da Cal S, Bissonnette P, Coady MJ, Lapointe JY. SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine. Am J Physiol-Gastr L 2007; 293: G1300-G1307.
14. Santer R, Kinner M, Lassen CL et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc of Nephrol 2003; 14: 2873-2882.
15. Scholl-Burgi S, Santer R, Ehrich JHH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transpl 2004; 19: 2394-2396.
16. Oemar B, Byrd D, Brodehl J. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin Nephrol 1987; 27: 156-160.
17. Paoli PD, Battistin S, Jus A et al. Immunological characterization of renal glycosuria patients. Clin Exp Immunol 1984; 56: 289-294.
18. Vestri S, Okamoto MM, de Freitas HS et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membrane Biol 2001; 182: 105-112.
19. +-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008; 149: 717-724.
20. Skyler JS. Insulin therapy in type 2 diabetes mellitus. In: DeFronzo RA, ed. Current Therapy of Diabetes Mellitus. St Louis, MO: Mosby-Year Book, 1998.
21. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes-Metab Res 2005; 21: 31-38.
22. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-1800.
23. Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 2009; 84: 111-118.
24. Katsuno K, Fujimori Y, Takemura Y et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmaco Exp Ther 2007; 320: 323-330.
25. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmaco Exp Ther 2008; 327: 268-276.
26. Dudash J Jr, Zhang X, Zeck RE et al. Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett 2004; 14: 5121-5125.
27. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
28. Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 6355-6360.
29. Tahara A, Kurosaki E, Yokono M et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. N-S Arch Pharmacol 2012; 385: 423-436.
30. Suzuki M, Honda K, Fukazawa M et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012; 341: 692-701.
31. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y et al. (1S)-1, 5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010; 53: 3247-3261.
32. Wilding J, Woo V, Soler NG, Pahor A, Sugg J, Parrikh S. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetologia 2010; 53(S1): S348-349.
33. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
34. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
35. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care 2010; 33: 2217-2224.
36. Tahrani AA, Barnett AH. Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther 2010; 1: 45-56.
37. Dobbins RL, O'Connor-Semmes R, Kapur A et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012; 14: 15-22.
38. Hussey EK, Clark RV, Amin DM et al. Single-dose pharmacokinetics and pharmacodynamics of Sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010; 50: 623-635.
39. Hussey EK, Dobbins RL, Stoltz RR et al. Multiple-dose pharmacokinetics and pharmacodynamics of Sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects. J Clin Pharmacol 2010; 50: 636-646.
40. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545.
41. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
42. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 Inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
43. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Diabetes Care 2009; 32: 1656-1662.
44. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012; 28: 1167-1171.
45. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
46. List JF, Woo VC, Villegas EM, Tang W, Fiedorek FT. Dapagliflozin-induced glucosuria is accompanied by weight loss in type 2 diabetes patients. Program and abstracts of the 68th Scientific Sessions of the American Diabetes Association, San Francisco, California June 6-10, 2008 (Abstract 461-P).
47. Administration TFaD. FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10 mg. Silver Spring, MD 20993-002 2011: P14-20
48. Burki TK. FDA rejects novel diabetes drug over safety fears. The Lancet 2012; 379: 507.
49. Administration TFaD. FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10mg. Silver Spring, MD 20993-002 2011: Statistical briefing material
50. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in [beta]-cell function. Nature 2001; 414: 788-791.
51. Yoon KH, Ko SH, Cho JH et al. Selective β-Cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-2308.
52. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
53. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
54. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
55. Macdonald FR, Peel JE, Jones HB et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010; 12: 1004-1012.
56. Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med 2012; 12: 995-1004.
57. Yamamoto K, Uchida S, Kitano K et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011; 164: 181-191.
58. Y mice. Eur J Pharmacol 2009; 618: 98-104.
59. Maedler K, Sergeev P, Ris F et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
60. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-276.
61. Jurczak MJ, Lee H-Y, Birkenfeld AL et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011; 60: 890-898.
62. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Safety 2007; 30: 1127-1142.
63. Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 2012; 7: e30555.
64. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes, Obesity and Metabolism 2012; 14: 539-545.
65. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
66. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocr Metab 2012; 97: 1020-1031.
67. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510-516.
68. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-Induced obese (DIO) rats. Obesity 2012; 20: 1645-1652.
69. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
70. Jabbour SA. The importance of reducing hyperglycemia while preserving insulin secretion-the rationale for sodium-coupled glucose co-transporter 2 inhibition in diabetes. US Endocrinology 2009; 5: 75-78.
71. Kasichayanula S, Chang M, Liu X et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther 2012; 29: 163-177.
72. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012; 9: 117-123.
73. Study AM. U.K. Prospective Diabetes Study: II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. Diabetes 1985; 34: 793-798.
74. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076.
75. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab; 12: 442-451.
76. Kawamori R, Inagaki N, Araki E et al. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. 70th ADA Scientific Sessions Orlando, Florida, USA 2010: 696-P.
77. Pfützner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011; 13: 567-576.
78. Kaku K, Inoue S, Matsuoka O et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013; 15: 432-440.
79. Ferrannini E. BI-10773 improves glycemic control in large study in type 2 diabetes. Diabetologia 2010; 53(Suppl. 1): Abst 877.
80. Zambrowicz B, Freiman J, Brown PM et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92: 158-169.
81. Zhang W, Welihinda A, Mechanic J et al. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res 2011; 63: 284-293.
82. Yao CH, Song JS, Chen CT et al. Discovery of novel N-β-d-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J Med Chem 2011; 54: 166-178.